Inhaled drug formulation involves consideration of multiple factors, including the properties of the API, the needs of the target patient population, the delivery requirements, and the choice of ...

Dublin, May 25, 2023 (GLOBE NEWSWIRE) -- The "Technology Innovations and Growth Opportunities in Inhaled Therapeutics" report has been added to ResearchAndMarkets.com's offering. Inhalation drug ...

Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announced that it has successfully dosed the ...

Capsugel, a global leader in delivering high-quality, innovative dosage forms and solutions, today announced that it has manufactured Phase 2 clinical trial supplies for a dry powder inhalation (DPI) ...

Please provide your email address to receive an email when new articles are posted on . The ICoN-1 trial has been discontinued, and futility was the reason for this decision. The company is still ...

To help pharmaceutical companies bring orally inhaled and nasal drug products (OINDPs) to market efficiently, scientific consultancy and contract research organization (CRO) Broughton announced a new ...

Biologics raise unique formulation and development challenges, and industry is still on a learning curve to get the best out of these diverse and complex therapies. The global biologics market has ...

Levalbuterol (as HCl) (single-isomer albuterol) 0.31mg/3mL, 0.63mg/3mL, 1.25mg/3mL, or 1.25mg/0.5mL (must be diluted); per vial; soln for inh via nebulization; preservative-free. Store Levalbuterol ...

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual ...

Capsugel has announced that it has manufactured Phase 2 clinical trial supplies for a dry powder inhalation (DPI) formulation that efficiently delivers biotherapeutics to the lung. The supplies were ...